News | February 24, 2009

BrachySciences Now Distributes All Three Isotopes for Low Dose Rate Prostate Brachytherapy

February 24, 2009 - BrachySciences, a provider of medical devices for the treatment of early stage prostate cancer, has signed a distribution agreement with IsoRay Inc. to distribute manufacturer of Proxcelan, making BrachySciences the only provider of all three radioactive isotopes used in low dose rate (LDR) prostate brachytherapy.

IsoRay’s Cesium-131 is the only radioactive source available for brachytherapy. BrachySciences has added Cesium-131 source to its distribution portfolio of Advantage Iodine-125 and the TheraSeed Palladium-103 device.

With access to all three isotopes and a diverse brachytherapy product portfolio capable of satisfying any pre-planned or real-time implant technique, BrachySciences has the ability to function as a solitary vendor and complete service provider to hospitals and clinics with LDR implant programs.

For more information: brachysciences.com

Related Content

California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | August 30, 2017
iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
iCAD, Xoft Axxent Electronic Brachytherapy System, eBx, 3,000 early-stage breast cancer patients, Miami Breast Cancer Conference
News | Brachytherapy Systems | March 15, 2017
CAD Inc. announced that more than 3,000 early-stage breast cancer patients have been treated with intraoperative...
prostate cancer, radiation therapy, high-dose-rate brachytherapy, HDR, Red Journal study

This is a single-fraction high-dose-rate prostate implant imaging and dosimetry. Image courtesy of Daniel Krauss/American Society for Radiation Oncology (ASTRO)

News | Brachytherapy Systems | March 06, 2017
March 6, 2017 — Results from a new prospective clinical trial indicate high-dose-rate (HDR)...
Elekta, Esteya electronic brachytherapy system, Radiation Oncology Centres, first in Australia, skin cancer
News | Brachytherapy Systems | January 16, 2017
On Dec. 8, 2016, a female patient in her 60s became the first in the Australia/New Zealand region to receive electronic...
Overlay Init